Icon

ZOKINVY (nda213969)- (50MG,75MG)

LONAFARNIB SENTYNL THERAPS INC
50MG,75MG
No No
2025-Oct-17 2025-Nov-20
None None
None No
ZOKINVY isa farnesyltransferase inhibitorindicatedin patients 12 months of age and older with a body surface area of 0.39 m2 and above: • To reduce risk of mortality in Hutchinson-Gilford Progeria Syndrome • For treatment of processing-deficient Progeroid Laminopathies with either: o Heterozygous LMNA mutation with progerin-like protein accumulation o Homozygous or compound heterozygous ZMPSTE24 mutations
0 0 0
Total Other Developers None
Drugs with Suitability No
50MG ** ** - - -
75MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.